Earnings Estimates Rising for Cushman & Wakefield (CWK): Will It Gain?
Cushman & Wakefield (CWK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cushman & Wakefield (CWK) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.
The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Cushman & Wakefield, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.
Current-Quarter Estimate Revisions
The earnings estimate of $0.58 per share for the current quarter represents a change of +34.88% from the number reported a year ago.
Over the last 30 days, three estimates have moved higher for Cushman & Wakefield compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 8.94%.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $1.60 per share, representing a year-over-year change of +97.53%.
The revisions trend for the current year also appears quite promising for Cushman & Wakefield, with three estimates moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 29.52%.
Favorable Zacks Rank
The promising estimate revisions have helped Cushman & Wakefield earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Investors have been betting on Cushman & Wakefield because of its solid estimate revisions, as evident from the stock's 7.6% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cushman & Wakefield PLC (CWK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research